INNOVATION at Heart
We share your passion to:
Improve outcomes and patient quality of life
Advance transcatheter structural heart therapies
Drive development of innovative technologies
COMMITMENT TO INNOVATION
WATCHMAN™ LAAC THERAPY
Review our portfolio of complementary TAVR technologies that enable physicians to expand their reach.
CAUTION: The LOTUS Edge Aortic Valve System is an investigational device. Limited by U.S. law to investigational use only. Not available for sale. The
Boston Scientific makes a
strategic investment in Millipede, Inc.
IRIS Annuloplasty Ring System
Transcatheter-based treatment for
severe mitral regurgitation.
LEARN MORE ›
WATCHMAN™ LAAC Device:
Five Year Results from PROTECT AF and PREVAIL
Published in JACC Demonstrated WATCHMAN
Reduced Risk of Stroke, Bleeding and Mortality*
*Comparable primary efficacy and all-cause stroke reduction, statistically significant reductions in disabling and fatal stroke (largely driven by reduction in hemorrhagic stroke), major non-procedure related bleeding as well as mortality, at 5 years vs. long-term warfarin therapy.
LEARN MORE ›
ACURATE neo™ Aortic Valve System:
Safey and efficacy results comparable
to SAPIEN 3 in MORENA,
a multicenter-comparison Study.1
1Husser O, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2078-2087.
Does Mild PVL Matter?
REPRISE III Analysis Shows Its Negative Impact on Stroke
EuroPCR 2018, See Dr. Linke's analysis on predictors of stroke in REPRISE III
(First US TAVR head-to-head IDE trial). LEARN MORE ›
BE PART OF OUR VISION
Join our community to receive updates and help us advance the treatment of structural heart therapies.